By simulating the life cycle of a minimal bacterial cell—from DNA replication to protein translation to metabolism and cell ...

Researchers have developed a capsule-based method that makes it possible to analyze the same cell through multiple experimental steps. The technology overcomes a long-standing limitation in cell ...

UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...

Solar manufacturers and project developers should be aware of an emerging and significant compliance risk concerning the origin of photovoltaic ...

A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...

Researchers have developed a capsule-based method that makes it possible to analyse the same cell through multiple experimental steps. The technology overcomes a long-standing limitation in cell ...

Scientists at Oregon Health & Science University have developed a new molecule that could open the door to treating triple-negative breast cancer, one of the most aggressive and difficult-to-treat ...

A University of Sydney-led research team has reported a new certified efficiency mark for large-area ...

Carotenoids like beta-carotene, lycopene, lutein, and zeaxanthin may improve skin, heart, and bone health or prevent prostate ...

Animals that dwell at high altitudes have adapted to cope with low oxygen levels, a condition that damages a vital part of nerve cells ...

Geroscience examines the underlying biology of aging to delay chronic diseases and extend the healthy years of human life.

Abeona Therapeutics (ABEO) stock gets a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. Read the full analysis here.